X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB   (REDY)

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) contributed 29% to sales. The balance was contributed by proprietary products. In February 2006, Dr.Reddy's acquired the German company Betapharm for US$ 570 m to mark its foray into the German generics market. Company has its operation in Russai & is ranked 12th in terms of market share.


American Depository Receipts Apr 19, 2018
Price (US$)32.48 Open (US$)32.69 High (US$)42.97 Low (US$)29.83
% Change0.22 Volume269,949 Value (US$)383,110 52-Week H/L36.06 / 36.38

DR. REDDYS LAB ADR Price Chart (US $) - 1 Year

Loading...

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Why India is Short of Cash Again(Vivek Kaul's Diary)

Apr 19, 2018

It is basically a supply problem with not enough currency going around in the financial system.

If Your Broker Calls You, Bang the Phone Down!(Smart Contrarian)

Apr 10, 2018

I'm going to tell you certain things about the inner workings of the industry so that you know why his advice is likely to be at best junk, and at worst dangerous.

How to Pick Great Stocks with Rajeev Thakkar(The 5 Minute Wrapup)

Apr 9, 2018

Rajeev Thakkar tells us how teachings from Vipassana can help you became a better investor.

How Small Caps Can Change the Way You Eat, Sleep, and Drive(Sector Info)

Apr 11, 2018

How you can increase your odds of seizing multibagger stocks and rake in the moolah by investing in small cap stocks.

This is How a Smart Robo-Advisor can Help You Chart Your Asset Allocation...(Outside View)

Apr 16, 2018

PersonalFN explains how a dependable robo-advisory platform can help you create your personalized asset allocation plan

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 20, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. REDDYS LAB

DR. REDDYS LAB 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE DR. REDDYS LAB WITH

MARKET STATS